1 / 9

Oxis – high safety margin

Oxis – high safety margin. Oxis – less systemic effect Pulse rate. 112. Formoterol 90 µg total dose Terbutaline 10 mg total dose. 108. Administration of formoterol/terbutaline. 104. 100. Administration of methylprednisolone. bpm. 96. 92. 88. 84. N = 36 adults

melia
Download Presentation

Oxis – high safety margin

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Oxis – high safety margin

  2. Oxis – less systemic effectPulse rate 112 Formoterol 90 µg total dose Terbutaline 10 mg total dose 108 Administration of formoterol/terbutaline 104 100 Administration of methylprednisolone bpm 96 92 88 84 N = 36 adults Randomized, parallel, double-blind Emergency room treatment of acute bronchoconstriction 0 60 120 180 240 300 360 720 Mins after first dose Malolepszy et al. Eur Respir J 2001

  3. Oxis – less systemic effectMean serum potassium 4.4 Formoterol 90 µg total dose Terbutaline 10 mg total dose 4.2 4.0 Administration of formoterol/terbutaline mmol/l 3.8 Administration of methylprednisolone 3.6 3.4 3.2 N = 36 adults Randomized, parallel, double-blind Emergency room treatment of acute bronchoconstriction 0 60 120 180 240 300 360 720 Mins after first dose Malolepszy et al. Eur Respir J 2001

  4. Oxis – less systemic effect Cardiac frequency Daily doses 84 Formoterol 54 µg 80 Formoterol 90 µg Terbutaline 6 mg 76 Cardiac frequency (beats/min) Terbutaline 10 mg 72 68 Dosing times 64 60 Day 1 Day 2 Day 3 Day 4 Tötterman et al, Eur Respir J 1998

  5. Oxis – less systemic effect Mean serum potassium 4.1 3.9 Serum potassium (mmol/l) Formoterol 90 µg/day 3.7 Terbutaline 10 mg/day 3.5 Dosing times 3.3 Day 1 Day 2 Day 3 Day 4 Tötterman et al, Eur Respir J 1998

  6. Oxis has short-acting systemic effects At comparable maximal effects, similar time profiles were observed 4.4 4.2 4.0 Serum potassium (mmol/L) dosing time 3.8 3.6 3.4 Oxis Turbuhaler 54 mg / day terbutaline Turbuhaler 6 mg / day 1 2 3 4 Days Tötterman et al, Eur Respir J 1998

  7. Oxis minimises systemic burden A schematic summary of clinical results arbitrary units Oxis Therapeutic effects short-acting ß2-agonists 0 6 12 short-acting ß2-agonists Time after dose (hrs) Oxis Systemic effects Derived from: 1. Ringdal N et al. Respir Med 19982. Palmqvist M et al. ERJ 1997 3. Borgström L et al. AJRCCM 1996 4. Tötterman KJ et al. ERJ 19985. Rosenborg J et al. Eur J Clin Pharmacol 2000 6. Malolepszy J et al. ERJ 2001

  8. Oxis is cost effective

  9. 4,000 3,500 3,000 2,500 2,000 1,500 1,000 500 Oxis as needed is cost-effective 3,709 3,386 cost of staying away from work duringa severe exacerbation health care costs for severe exacerbations Cost per patient for a 12 week treatment (SEK) inhaled and oral steroids study drug costs N = 362 asthmatics formoterol 4.5 g and terbutaline 0.5 mg used as needed Oxis Turbuhaler Terbutaline Turbuhaler Berggren et al. Respir Med 2001

More Related